




EU Innovation Network

Core profile within the network





New NCAs* from September 2016 to date

The Czech Republic – October 2016

Germany (BfArM) – October 2016

Denmark – November 2016


Norway – March 2017

Estonia – April 2017

Poland – April 2017

Croatia – May 2017

* Please note that changes to appointed EU-IN members representing NCAs Innovation Offices are not highlighted here.



Target products

Chemical medicines (90%)

Biological medicines (95%)

Vaccines (85%)

ATMPs (90%)

Generic medicines (80%)

Biosimilar medicines (70%)

Combined/borderline (95%)

Medical devices (50%)

Innovative methods and tools
for drug development (70%)

The EU Innovation offices Network focuses on
HUMAN health products.

Innovation offices welcome a **large variety** of health
products provided they contain some innovative
features (scientific, technological or therapeutics)

Medical devices are addressed in 50% of the offices
and will be made soon eligible in one additional
office.

One office works also on cosmetics.

Target products

Chemical medicines (92%)

Biological medicines (100%)

Vaccines (83%)

ATMPs (92%)

Generic medicines (75%)

Biosimilar medicines (75%)

Combined/borderline (92%)

Medical devices (50%)

Innovative methods and tools
for drug development (75%)

Target groups

Academic research
laboratories (100%)

Hospital units (100%)

Start-ups (100%)

SMEs (100%)

National/International groups
(85%)

Consortia (65%)

Consulting groups (65%)

The services of the Innovation Support Offices are directed to hospitals, academic groups and SMEs, research foundations, consortia.

Some have also expressed their willingness to hear from Patient interest groups and or funding/networking organisations.

Target products

- Chemical medicines (92%)
- Biological medicines (100%)
- Vaccines (83%)
- ATMPs (92%)
- Generic medicines (75%)
- Biosimilar medicines (75%)
- Combined/borderline (92%)
- Medical devices (50%)
- Innovative methods and tools for drug development (75%)


Target groups

- Academic research laboratories (100%)
- Hospital units (100%)
- Start-ups (100%)
- SMEs (100%)
- National/International groups (100%)
- Consortia (67%)
- Consulting groups (67%)

Focus

- Quality/viral safety (100%)
- Preclinical (100%)
- Clinical (100%)
- Production process (90%)
- Pharmacovigilance (80%)
- Help to make the redaction of documents (25%)
- Import / export (55%)
- Regulatory processes (100%)
- HTA/reimbursement – Payers (40%)

The scope is wide and includes along the lifecycle of products manufacturing processes, redaction of documents, facilities, GMP, import/export issues, antimicrobials, biostatistics, preparations for scientific advice meetings, Pharmacovigilance, and HTA/Payers interactions







Thank you for your attention

Further information

Heads of Medicines Agencies www.hma.eu

European Medicines Agency www.ema.europa.eu

